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ABSTRACT
Several reports described an increased risk of cardiovascular (CV) events, mainly 
atherothrombotic, in Chronic Myeloid Leukemia (CML) patients receiving nilotinib. 
However, the underlying mechanism remains elusive. The objective of the current 
cross-sectional retrospective study is to address a potential correlation between 
Tyrosine Kinase Inhibitors (TKIs) treatment and CV events. One hundred and 10 chronic 
phase CML patients in complete cytogenetic response during nilotinib or imatinib, 
were screened for CV events and evaluated for: traditional CV risk factors, pro/anti-
inflammatory biochemical parameters and detrimental ORL1 gene polymorphisms 
(encoding for altered oxidized LDL receptor-1). Multivariate analysis of the whole 
cohort showed that the cluster of co-existing nilotinib treatment, dyslipidaemia and 
G allele of LOX-1 polymorphism was the only significant finding associated with CV 
events. Furthermore, multivariate analysis according to TKI treatment confirmed 
IVS4-14 G/G LOX-1 polymorphism as the strongest predictive factor for a higher 
incidence of CV events in nilotinib patients. Biochemical assessment showed an 
unbalanced pro-inflammatory cytokines network in nilotinib vs imatinib patients. 
Surprisingly, pre-existing traditional CV risk factors were not always predictive of 
CV events. We believe that in nilotinib patients an induced “inflammatory/oxidative 
status”, together with a genetic pro-atherothrombotic predisposition, may favour 
the increased incidence of CV events. Prospective studies focused on this issue are 
ongoing.
INTRODUCTION
The great improvement in survival expectancy in 
Chronic Phase (CP) Chronic Myeloid Leukemia (CML) 
patients chronically treated with Tyrosine Kinase Inhibitors 
(TKIs) has prompted the clinical issue of long-term drug 
toxicity, safety and quality of life [1-3]. While imatinib has 
been generally well tolerated with an adverse effect profile 
stable over the years [1], long-term side effects of second 
and third generation TKIs are not completely defined yet 
and especially cardiovascular (CV) adverse events related 
to their use are a matter of concern [4-6]. Several recent 
retrospective clinical studies reported a higher incidence 
of atherothrombotic events including peripheral arterial 
occlusive disease (PAOD) in CML patients treated with 
nilotinib when compared to imatinib or dasatinib; these 
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peculiar adverse events appear to increase over time 
during continuous nilotinib treatment [6-13]. Preliminary 
experimental data suggest that nilotinib, in contrast to 
imatinib, may cause direct pro-atherogenic, growth-
inhibitory and thus anti-angiogenic effects on vascular 
endothelial cells [14]. However, the pathogenic link 
between nilotinib and atherothrombosis has not been fully 
elucidated and more work is needed to better understand 
the effects of nilotinib in preclinical CV models. From a 
clinical point of view, whether atherothrombotic events 
occur predominantly in CML patients with pre-existing 
traditional CV risk factors is a matter of debate as most 
studies are based on retrospective data and the risk factors 
rate for arterial occlusive disease varied significantly 
[15-19]. We have also taken into consideration that, 
according to various reports, the percentage of patients on 
nilotinib treatment with pre-existing CV risk factors who 
experienced atherothrombotic events ranged anywhere 
from over 90% down to 20% [9, 16, 17, 19, 20]. 
Given such heterogeneity of findings and clinical 
experience, we studied patients receiving TKIs treatment, 
in order to identify if the vascular events could be 
associated to a genetic predisposition and/or a drug 
induced pro-atherothrombotic effect, independently of the 
presence of traditional CV risk factors. 
Arterial occlusive disease is mainly caused by 
atherosclerosis, a multifactorial disease of the vessels 
involving lipid and other metabolic disturbances, 
thrombogenic components, cell death and inflammatory 
responses of the arterial wall [21]. Metabolic and 
pro-inflammatory factors share a relevant role in the 
pathogenesis of atherothrombotic events mainly via 
enhanced lipid peroxidation [22]. Lectin-like oxidized-
LDL (ox-LDL) receptor-1(LOX-1), is the main receptor 
for the pro-atherogenic ox-LDL [22-25]; it is expressed 
in endothelial cells, macrophages, platelets and vascular 
smooth muscle cells, all relevant cellular effectors of 
atherogenesis and atherothrombosis mechanisms [22-25]. 
LOX-1 gene, named OLR1, is mapped on chromosome 
12p 13.2-p12.3 and different studies demonstrated that 
OLR1 single nucleotide polymorphisms (SNPs) may 
cause susceptibility to coronary artery disease (CAD), 
particularly in Caucasian ancestral populations [23]. 
In particular, the IVS4-14 A/G polymorphism, which 
acts in complete linkage-disequilibrium with other five 
polymorphisms located in the introns 4, 5 and 3’UTR 
region, has been implicated in geographic disparities in 
CV event rate [24].
Thus, to elucidate a potential pathogenic link 
between TKIs treatment and mechanisms underlying 
PAOD or other atherothrombotic events, we investigated, 
in a series of CML patients treated with nilotinib and 
imatinib, the correlation between LOX-1 polymorphisms, 
the presence of classic CV risk factors and vascular 
events. Furthermore, during treatment with either TKIs, 
we studied a selected pro-atherothrombotic biochemical 
profile evaluating the following: 1) coagulation state 
by Endogenous Thrombin Potential (ETP); 2) specific 
circulating mediators of inflammation such as IL-10, IL-6 
and TNFα; 3) high-sensitivity C-reactive protein (hs-CRP) 
previously proven to be involved in the atherothrombosis 
burden [22-27]; 4) ox-LDL as metabolic effectors of 
atherosclerosis predisposition [22, 23, 25]; 5) soluble 
CD40 ligand (sCD40L) as a marker of platelet derived-
inflammation and platelet activation trigger [22, 28]. 
RESULTS
Whole patients cohort data and multivariate 
analysis
One hundred and ten consequent CP CML patients 
in complete cytogenetic response (CCyR), willing to 
participate in the study, were evaluated. In order to 
consider a homogeneous cohort, to have the least active 
cancer-related thrombotic risk and to minimize any 
cytokine unbalance due to different CML cell burden at 
study evaluation, we included only CCyR patients.
Clinical characteristics, risk factors distribution and 
incidence of CV events are summarized in Table 1. The 
incidence of two or more traditional CV risk factors was 
56%. LOX-1 genotype frequency in the whole cohort of 
patients respected the Hardy-Weinberg equilibrium that 
is present in ancestral Caucasian origin populations [24] 
(Table 2). Atherothrombotic events occurred in 17/110 
(15%) patients thus counting for a consistent sample size 
for multivariate analysis. We took in consideration the 
TKI treatment at the time of any CV event or, if no event 
occurred, at the time of study visit: 58 patients were on 
imatinib and 52 on nilotinib treatment. 
Whole cohort multivariate analysis
The Cox Hazard model and the Hosmer-Lemeshow 
confirmation test, once corrected for each applicable data 
(age, gender, body mass index (BMI), single or clustered 
risk factors including smoking habit, CV medications, 
LOX-1 polymorphism, TKI treatment) available at 
the time of occurring event or at the time of clinical 
observation if event-free, showed that the cluster of co-
existing nilotinib treatment, dyslipidaemia and the G allele 
of LOX-1 polymorphisms was the only significant finding 
associated with events (H.R. 2.19 95% C.I. 1.66-2.99, p 
< 0.001) (Figure 1). Furthermore, in patients with two or 
three traditional risk factors, no CV events occurred during 
treatment with either TKIs whether not coupled with both 
G allele of LOX-1 and dyslipidaemia (Figure 1).
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Figure 1: Relations among end-points and nonparametric data in the whole cohort of CML patients treated with 
TKIs (n= 110). Cox proportional-hazards modeling and formal test for interaction: starting from logistic regression analysis in which 
Y was the analyzed variable (both parametric such as age and BMI); the variables X1 and X2 were the presence or absence (1 or 0) of the 
LOX-1 polymorphism or other non-parametric variables (drugs, history of cardiovascular classical risk factors, here named TCRF, and 
X3 the combination). The simplified formula for calculation was: Y = β0+β1X1+β2X2+β3X3 and the null hypothesis was tested as H0: β3 = 0. 
Final data validation  has been assessed with a resampling technique (exact tests) and discrimination analysis with the Hosmer–Lemeshow 
method [G2HL= ∑
10
J=1
 (Oj – Ej)
2/Ej (1-Ej/nj) ∼X28], where nj = number of observations in the jth group, Oj = ∑1yij = observed number of 
positive cases in the jth group, Ej = ∑pij = Expected number of positive cases in the jth group. (Each reported p is obtained by this technique 
and considered significant if < 0.05)
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Patients data and multivariate analysis according 
to TKI treatment
Following the evidence that nilotinib treatment 
was a favoring factor for vascular events in the whole 
cohort, we further analyzed putative differences among 
clinical and genetic variables according to imatinib or 
nilotinib treatment. As reported above, at the time of any 
CV event or, if no event occurred, at the time of study 
visit, 58 patients were on imatinib and 52 on nilotinib 
treatment (Table 1). As expected from a “real life” 
unselected study population, the duration of the disease 
and the TKI exposure were significantly longer in the 
imatinib cohort when compared to the nilotinib cohort 
(Table 1). Additionally, 45% of nilotinib patients were on 
second-third line treatment. The distribution of traditional 
CV risk factors showed a slightly higher prevalence of 
dyslipidaemia in the nilotinib cohort. Similarly, having 
three or more CV risk factors was a more frequent 
observation in such group (Table 1). 
An atherothrombotic event occurred in 3/58 (5%) 
imatinib treated patients (1 PAOD, 2 carotid occlusion > 
50%), and in 14/52 (27%) patients in the nilotinib cohort 
(9 PAOD, 5 acute coronary syndrome) (Table 1). All three 
events in the imatinib group occurred during first line 
treatment, while 6/14 (43%) and 8/14 (57%) of events 
recorded in the nilotinib cohort occurred during first and 
second-third line treatment, respectively. Time from TKI 
exposure to CV event was 125, 132 and 102 months for 
the three patients receiving imatinib while median time of 
nilotinib exposure to event was 30 months (range 18-72) 
(Table 1).
LOX-1 polymorphism distribution
Considering the genotype frequency according to 
TKI treatment, we found a slight excess of homozygotes 
A/A in the imatinib group and a significant excess of 
homozygotes G/G in the nilotinib treated cohort (Table 
2). However, it has to be noted that 23 nilotinib patients 
switched from a previous treatment with imatinib, thus 
if we consider G/G frequency according to first line 
therapy we found a similar distribution of the LOX-1 G/G 
polymorphism between the two treatment groups (imatinib 
first line treated cohort n = 81, G/G n = 10 = 12.4%; G.F./
A.F. 0.148/0.184; nilotinib first line treated cohort n = 29, 
G/G n = 4 = 13.8%, G.F./A.F. 0.156/0.193, no statistically 
significant difference). Interestingly, the homozygotes G/G 
Table 1: Clinical characteristics and risk factors distribution of patients during TKI treatment or at the time of 
cardiovascular event. 
whole cohort imatinib cohort nilotinib cohort p
N° Patients 110 58 52 0.094
M/F 66/44 31/27 35/17 0.061
Median age (years, range) 61 (29-83) 59 (33-82) 62 (29-83) 0.088
Median duration of CML (months, range) 60 (3-252) 84 (12-180) 56 (3-228) 0.019
Median TKI exposure (months, range) n.a. 84 (12-180) 24 (3-84) 0.0014
First-line (%) n.a. 58 (100) 29 (55) 0.0029
Second-third line TKI (%) n.a. 0 (0) 23 (45) n.a.
History of smoking (%) 34 (31) 17 (29) 17 (33) 0.126
Arterial Hypertension (%) 36 (33) 17 (29) 19 (37) 0.054
Diabetes Mellitus (%) 19 (17) 9 (16) 10* (19) 0.088
BMI (range) 26±1,4 26,1±1,4 25,9±1,3 0.091
Dyslipidaemia (%) 35 (32) 15 (26) 20 (38) 0.047
Familiarity (%) 58 (53) 30 (52) 28 (54) 0.099
Number of risk factor > 2
Number of risk factor ≥ 3
62 (56)
44 (40)
29 (50)
18 (31)
33 (63)
26 (50)
0.048
0.041
Total n° of cardiovascular events (%) 17/110 (15) 3/58 (5) 14/52 (27) 0.00011
First line treatment (%) n.a. 3/58 (5) 6/29 (21) n.a.
Second-third line (%) n.a. 0/0 (0) 8/23 (35) n.a.
TKI treatment time to event (months) 125, 132, 102 30 (range 18-72) n.a.
Abbreviation: CML chronic myeloid leukemia, TKI tyrosine kinase inhibitor, BMI body mass index, n.a. not applicable *2/10 
glucose intolerance
Oncotarget72315www.impactjournals.com/oncotarget
clustered in the first and second line nilotinib sub-group 
of patients experiencing an atherothrombotic event during 
treatment (Table 2). 
Multivariate analysis
The Cox Hazard model and the Hosmer-Lemeshow 
confirmation test, once corrected for each applicable 
data (age, gender, BMI, single or clustered risk factors 
including smoking habit, CV medications, LOX-1 
polymorphism) available at the time of event recording 
or at the time of clinical observation if event-free, showed 
that the single influencing risk factor was the G/G 
homozygosis for IVS4-14A/G of OLR1 in the nilotinib 
group (Figure 2). No significant influence on vascular 
event rate was detected for any single traditional CV 
risk factor, despite the slightly increased prevalence of 
dyslipidaemic subjects in the nilotinib group (Figure 2, 
Table 1). 
Biochemical analysis according to TKI treatment
The biochemical analysis was performed during 
follow-up visit in all 110 patients, yet it has to be 
underlined that after an atherothrombotic event some 
clinicians decided to switch TKI due to the adverse 
event. Thus biochemical assessment was performed in 
65 patients on imatinib (7 of them has been previously 
treated with nilotinib) and in 45 patients on nilotinib 
treatment. Patients with a history of CV events underwent 
biochemical analysis after at least 6 months from the event 
(median time 12 months, range 6-60 months). As shown in 
Table 3, ox-LDL, sCD40L level and ETP, in close linear 
relation among each other, (Supplemental Table S1), were 
significantly higher in nilotinib vs. imatinib treated group, 
while IL-10 level, inversely related to ox-LDL, sCD40L 
and ETP (Supplemental Table S1), was significantly lower. 
No statistically significant differences were found 
in the expression of IL-6 and TNF-α between the two 
groups (Table 3). Interestingly, we observed no statistical 
difference in the cytokine profile between patients who had 
always been treated with imatinib and those 7 patients that 
were on imatinib at the time of biochemical assessment 
but experienced a CV event during nilotinib (Table 3).
The influence of CV risk factors and ongoing 
medications for CV risk control on the biochemical 
profile of all CML patients was also assessed. In the 
nilotinib cohort ox-LDL, sCD40L, ETP and IL-10 levels 
showed a similar pattern in patients with CV risk factors 
and concomitant CV drugs as well as in those without 
risk factors and no related treatment (Supplemental Table 
S1 and S2). Thus, the detrimental biochemical profile 
observed in nilotinib treated patients was unrelated to the 
underlying CV risk and remained significantly different 
from that observed both in the imatinib treated cohort and 
in the non-CML matched controls (Supplemental Table S1 
and S2). 
Conversely, fasting plasma glucose, lipid profile 
(including LDL) and hs-CRP were not significantly 
different between imatinib and nilotinib treated group, 
regardless of the presence of CV risk factors and related 
treatments (Table S1). 
DISCUSSION
Recently, the high occurrence of CV toxicity mainly 
related to atherothrombotic events during second and third 
generation TKIs treatment has prompted the interest and 
concern of clinicians caring for CML patients [13, 29]. 
Table 2: Distribution of oxidized-LDL receptor-1 (LOX-1) polymorphisms (IVS4-14 A/G) in study population.
all patients imatinib whole cohort (event cohort)
nilotinib whole cohort 
(event cohort) p°
N° Patients 110 58 (3) 52 (14)
A/A LOX-1 polymorphism 33 22 (0) 11 (0) 0.046
A/G LOX-1 polymorphism 63 34 (2) 29 (2) 0.081
G/G LOX-1 polymorphism 14 2 (1) 12 (12) 0.00021
A/A LOX-1 polymorphism 
(G.F. /A.F.) *(0.300/0.195)
§ (0.379/0.270) *(0.211/0.156) (p = 0.048)
A/G LOX-1 polymorphism 
(G.F./A.F.) *(0.572/0.642)
§ (0.586/0.688) *(0.557/0.601) (p = 0.094)
G/G LOX-1 polymorphism 
(G.F./A.F.) *(0.128/0.163)
§ (0.034/0.042) *(0.230/0.243) (p =  0.0038)
G/G Genotype/Events 
relation * p= 0.085 p = 0.0094
Abbreviation : LOX-1 oxidized-LDL receptor-1; G.F. genotype frequency;  A.F. allele frequency * χ2 test of independence 
(§  p = n.s. with respect to HapMap CEU, downloaded from http://www.hapmap.org.genotypes/ and Italian population) ° 
Mann-Whitney U test.
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Figure 2: Relations among end-points and nonparametric data in imatinib treated (n=58) and nilotinib treated (n=52) 
CML patients. Cox proportional-hazards modeling and formal test for interaction: starting from logistic regression analysis in which Y 
was the analyzed variable; the variable X1 and X2 were the presence or not (1 or 0) of the LOX-1 polymorphism or other non-parametric 
variables (history of cardiovascular classical risk factors, here named TCRF, and X3 the combination). The simplified formula for calculation 
was: Y = β0+β1X1+β2X2+β3X3 and the null hypothesis was tested as H0: β3 = 0. Final validation of data was assessed by a resampling 
technique (exact tests) and discrimination analysis by the Hosmer–Lemeshow method [G2HL= ∑
10
J=1
 (Oj – Ej)
2/Ej (1-Ej/nj) ∼X28], where nj 
= number of observations in the jth group, Oj = ∑1yij = observed number of positive cases in the jth group, Ej = ∑pij = Expected number of 
positive cases in the jth group. (Each reported p is that obtained by this technique and significant if < 0.05)
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However, the trigger of these serious adverse events has 
not fully clarified yet. In this preliminary cross-sectional 
study including a series of 110 CML patients treated with 
imatinib or nilotinib, we found that the cluster of co-
existing nilotinib treatment, dyslipidaemia and the G allele 
of LOX-1 polymorphism was the only significant finding 
associated with atherothrombotic events. 
As nilotinib appeared to be a possible causing 
factor for vascular events of the overall population, we 
further performed a multivariate analysis according to TKI 
treatment including age, gender, BMI, single or clustered 
risk factors, CV medications, LOX-1 polymorphism. The 
latter confirmed that the detrimental IVS4-14 G/G LOX-
1 polymorphism was the strongest predictive factor for a 
higher incidence of atherothrombotic events in nilotinib 
treated patients (i.e. 14/52 (27%) vs. 3/58 (5%) events 
in nilotinib and imatinib treated patients, respectively). 
To our surprise, we found no clear correlation of 
traditional CV risk factors other than dyslipidaemia 
with atherothrombotic events. Indeed, we found that 
12/14 (86%) of nilotinib patients with vascular events 
had G/G variant genotype, whereas among 26 nilotinib 
patients with ≥3 traditional risk factors, only 9/26 (35%) 
experienced an atherothrombotic event, thus implying 
a possible role for a different genetic profile. The 
distribution of LOX-1 IVS4-14 A/G polymorphisms of the 
whole CML population showed a close correlation with 
previously described Caucasian populations epidemiologic 
data [24]. However, with respect to treatment, the G/G 
distribution apparently clustered in the nilotinib treated 
cohort (Table 2) thus inferring a possible bias in the 
patients’ selection. Against this hypothesis is the lack of 
significant between-group difference in the allelic and 
genetic frequency of LOX-1 when we considered patients 
during first line treatment (81 imatinib, 29 nilotinib) (Table 
2). The apparent segregation of G/G in the nilotinib group 
may be due to the fact that eight G/G patients treated in 
first line with imatinib without evidence of any vascular 
event, were then switched to nilotinib (due to intolerance 
or no response) and only afterward experienced an event. 
From a pathogenic point of view, it is known 
that dysfunctional LOX-1 derived from specific 
detrimental SNPs in the OLR-1 gene, such as the IVS4-
14 A/G evaluated in our study, strongly exerts pro-
atherothrombotic effects via disturbances of ox-LDL 
metabolism [23]. Indeed ox-LDL is the most active pro-
atherogenic and pro-thrombotic form of lipoproteins 
and the process of lipid peroxidation is induced mainly 
by inflammatory stimuli [22, 30-33]. Therefore, in this 
study we have also performed a cross-sectional analysis 
of a selected pro-inflammatory/pro-oxidative biochemical 
profile during TKIs treatment. Firstly, we provided 
biochemical evidence of a pro-atherothrombotic profile 
in patients on nilotinib treatment, as highlighted by the 
increased sCD40L levels, and a concurrent (and correlated) 
enhancement of thrombin generation as compared to 
imatinib treated patients and matched controls. Indeed 
sCD40L increase was significantly associated with 
enhanced lipid peroxidation, as reflected by higher ox-
LDL levels, suggesting that lipid peroxidation can be 
a relevant molecular link between inflammation and 
thrombosis [33]. Secondly, systemic inflammation also 
appeared to be enhanced, as reflected by higher hs-CRP 
levels in nilotinib treated subjects, although not reaching a 
statistical between-group significance. The evidence of an 
underlying pro-inflammatory state was also documented 
by the reduction of the anti-inflammatory cytokine IL-
10 in the nilotinib cohort. In fact, the reduction of IL-10 
has been described as a pro-atherogenic inflammatory 
condition [34] whereas hs-CRP is not a universal predictor 
of CV risk [35] and its levels are strictly related to IL-6 
rather than other cytokines production [36]. Our data also 
showed a significant increase of ox-LDL levels in the 
nilotinib cohort of patients; this may not be due to higher 
circulating LDL levels but to an increased pro-oxidative, 
inflammatory- and genetically-driven state [37]. The 
finding of an increased ox-LDL level is of interest because 
it is independently associated with atherothrombotic 
events, regardless of classical parameters of lipid profile. 
In the general population, ox-LDL levels improved the 
Table 3: Biochemical pro-inflammatory/pro-atherothrombotic evaluation according to TKI treatment at study visit.
imatinib whole 
cohort
nilotinib whole 
cohort p
imatinib
(previously treated 
with nilotinib)
P
(vs. always treated with 
imatinib n. 58)
N° Patients 65 45 7
oxLDL (UI/L) 69.9±7.1 92.2±9.9 0.0022 71.4±8.8 0.097
IL6 (pg/ml) 8.8±1.33 9.9±1.44 0.091 8.5±1.67 0.094
IL10 (pg/ml) 4.86±1.17 1.06±0.58 0.00012 4.59±1.23 0.081
TNFα (pg/ml) 9.6±1.8 10.8±1.93 0.094 9.9±1.9 0.088
sCD40L (pg/ml) 330.5±59.2 513.3±91.9 0.0023 336.4±55.2 0.090
ETP (%) 7.3±1.82 14.7±3.73 0.0019 7.4±1.93 0.104
hs-CRP (mg/dl) 1.02±0.17 1.14±0.21 0.076 1.09±0.14 0.070
Abbreviation: oxLDL oxidized-LDL, IL interleukin, TNFα tumor necrosis factor alpha, sCD40L soluble CD40 ligand, ETP 
Endogenous Thrombin Potential, hs-CRP high-sensibility C reactive protein.
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reclassification capacity of Framingham-derived CAD risk 
functions [31, 32], however in our experimental model 
we could not estimate CV risk with this or other specific 
algorithms [38, 39] due to the lack of baseline data. 
Further evidence from specifically-designed prospective 
studies are needed to better clarify the involvement of 
traditional risk factors clustering in the development of 
atherothrombotic events during TKIs. An additional 
suggestion emerges from our study: in nilotinib patients 
with ongoing treatment for CV risk factors there was no 
apparent positive effect of CV and anti-atherothrombotic 
drugs on the altered ox-LDL, sCD40L, ETP and IL-10 
levels.
Increase of IL-10 levels may induce an anti-
atherogenic profile of LOX-1 in terms of reduction of 
ox-LDL uptake and minor vascular damage [40]. Thus, 
we have hypothesized that the pro-atherothrombotic 
risk during nilotinib could arise from the combination 
of increased lipid peroxidation due to detrimental LOX-
1 polymorphism and an imbalance in cytokine-driven 
inflammation, mainly exerted by the strong reduction of 
IL-10 levels [40].. Furthermore, the activation of LOX-1 
by oxLDL induces up-regulation of monocyte chemotactic 
factor (MCP)-1, intercellular adhesion molecule (ICAM)-
1 and vascular cell adhesion molecule (VCAM)-1 [25, 41]. 
In this regard, Valent et al. suggest that other mechanisms 
potentially are involved in vascular disease during TKIs 
treatment [14]. They demonstrated that high levels of 
VCAM-1 molecules are expressed in vascular cells in 
nilotinib treated mice, providing a possible nilotinib “off 
target” effect [14].. 
If confirmed, this direct effect could be involved in 
the acceleration of plaque formation and/or destabilization 
and could synergize with the endothelial dysfunction 
induced by the altered LOX-1 activity and inflammatory 
state [25, 41]. 
CONCLUSIONS
The combination of genetic and biochemical data 
here reported may provide a possible clue to unravel the 
underlying mechanism of atherosclerotic vascular events 
occurring in some nilotinib treated patients. To further 
confirm our pathogenic hypothesis we started a large 
multicenter prospective study in CP CML patients treated 
with any of the first line approved TKI in which pro-
atherothrombotic genetic status, traditional CV risk factors 
and biochemical profile, will be evaluated from baseline 
and monitored during treatment. The ultimate goal of this 
study is to provide a genetic and biochemical tool that 
will aid clinical evaluation in identifying patients with 
relevant atherothrombotic risk earlier and better, in order 
to offer them the most effective, yet safest, personalized 
TKI treatment.
MATERIAL AND METHODS
Patient population
Between May 2013 and October 2013, all 
consecutive patients with CP-CML referring to our out-
patient clinic for a routine follow-up visit during imatinib 
or nilotinib treatment, with CCyR and with various degree 
of molecular response, were recruited for the study. 
Written informed consent was obtained in all subjects. 
Each participant was evaluated for: presence and onset-
time of traditional CV risk factors (diabetes mellitus, 
dyslipidaemia, arterial hypertension, BMI, smoking 
habit, family history for vascular events); concurrent 
medications; presence of PAOD and other CV events 
occurring during TKIs treatment. An atherothrombotic 
event was taken into consideration if any of the following 
occurred: PAOD, acute cardiac syndrome, atherosclerotic 
cerebral ischemia and carotid atherosclerosis (stenosis 
> 50%). At the same time peripheral blood and serum 
samples were obtained to assess the following: intron 4 
IVS4-14 A > G polymorphisms of OLR1 (rs3736235), 
distribution of genotypes AA (low risk), AG and GG (high 
risk); sCD40L, ox-LDL, IL-6, IL-10, TNF-α, hs-CRP, 
ETP, complete lipid profile (including LDL calculated by 
the Friedewald’s formula) and fasting plasma glucose.
Genetic analysis
Genomic DNA from peripheral blood leukocytes 
was extracted using the NucleoSpin Blood QuickPure Kit 
(MACHEREY-NAGEL). All samples were genotyped for 
the OLR1/Intron4 IVS4-14 A > G polymorphism by allelic 
discrimination assay using the TaqMan SNP Genotyping 
Assay (rs3736235; Applied Biosystem) 
Biochemical analysis
Plasma samples for biochemical analysis were 
harvested after centrifugation within two hours from 
blood collection and immediately stored at -80°C until 
processing. 
Endogenous thrombin potential (ETP)
ETP was measured in platelet-poor plasma using 
a commercially available assay (Siemens, Marburg, 
Germany) in a BCS-XP System (Siemens, Marburg, 
Germany) according to manufacturer instructions. 
Coagulation activation was initiated by incubation of 
plasma with phospholipids, human recombinant tissue 
factor (Innovin; Siemens, Marburg, Germany), and 
calcium ions in the absence of thrombomodulin. The 
concentration of phospholipids and tissue factor is 
confidential to the manufacturer. Thrombin generation 
Oncotarget72319www.impactjournals.com/oncotarget
and subsequent inactivation was recorded by monitoring 
conversion of a specific slow reacting chromogenic 
substrate at a wavelength of 405 nm over time. 
Soluble CD40 ligand
sCD40L was evaluated according to manufacturer 
instructions as previously reported and specific 
recommendations regarding the appropriate specimen and 
preparation for laboratory evaluation by Platinum ELISA 
kits from eBioscience, Ltd. (Hatfield, Ireland, United 
Kingdom) were used. 
IL-6, TNF alpha, IL-10, ox-LDL
According to each manufacturer’s specifications, 
IL-6 and TNF-α plasma levels were determined by using 
the high sensitivity Quantikine ELISA assays (R&D 
systems, Minneapolis, Minnesota); the Platinum ELISA 
kit from eBioscience, Ltd. (Hatfield, Ireland, United 
Kingdom) was employed for IL-10; oxLDL levels were 
determined by using ox-LDL Immundiagnostik AG - 
Bensheim, Germany ELISA Kit.
High-sensitivity C-reactive protein
Serum hs-CRP levels were measured using 
an available high sensitivity-CRP commercial kit 
(Siemens, CardioPhase, Marburg, Germany) based on an 
immunonephelometry assay.
ELISA equipment
Each ELISA test was performed on a Bio-Rad iMark 
Microplate Absorbance Reader (Biorad, Hercules, CA) 
except for sCD40, IL-10 and ox-LDL assays that were 
done on DSX automatized processor (DSX™, Bouty-
Technogenetics Milan, Italy), provided by a specific 
software to perform the entire analytical process. All 
ELISA samples were assayed in duplicates.
Statistical analysis
The Cox proportional-hazards modelling was used 
to evaluate the putative relations among end-points and 
the nonparametric data such as the genetic trait in the 
whole cohort of 110 subsequent CP CML patients in 
CCyR. For this purpose, the calculated number to detect 
a significant difference in parametric and not parametric 
variables, including genetic trait, evaluated, with 90% 
power at p = 0.01 was 96, if at least 14 events would 
occur. Accordingly, the statistical model consisting of a 
formal test for interaction was employed to determine the 
putative relation for each single variable. Final validation 
of data was assessed by a resampling technique (exact 
tests in SPSS 2003 module) and discrimination analysis 
by the Hosmer-Lemeshow method assuming a p < 0.05 as 
indicating a statistical significance. Furthermore, assuming 
a putative 10% difference in the frequency of events in 
association with each analyzed variable (single or cluster), 
according to previous data [42] and reported incidence and 
prevalence of PAOD in the general Caucasian population 
affected by traditional CV risk factors stratified for age 
[43], the calculated sample size to detect a significant 
difference in the genetic variables evaluated, with 90% 
power at p = 0.01, was 51 for each putative arm emerging 
from the whole cohort analysis.
To estimate putative differences in the levels of 
each single biochemical variable we employed the Mann 
Whitney U-test and the Wilcoxon test for comparisons 
between and within groups. The Kendall rank correlation 
coefficient was used to measure the relationship among 
measurable variables. Differences in genotype and allele 
proportion of the population and differences between 
observed and expected genotype frequencies (assuming 
Hardy-Weinberg equilibrium) were evaluated by χ2 test of 
independence. All calculations were performed using the 
SPSS library version 13 (SPSS Inc. Chicago, IL).
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